1Y Close · As of Aug 26, 2026
Aprogen operates in the Pharmaceuticals sector.
Legal name: Aprogen, Inc
In fiscal year 2025, Aprogen (007460) reported revenue of 118.0 billion KRW, down 21.4% from 150.1 billion KRW a year earlier.
Operating profit was -95.6 billion KRW and net income was -140.6 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 67.0 billion KRW, with a P/B of 0.15.
These figures can be verified in the DART filing (receipt no. 20260323001476).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 118.0B | -95.6B | -140.6B |
| 2024 | 150.1B | -86.8B | -100.4B |
| 2023 | 150.6B | -88.9B | -97.3B |
Recent Filings
유상증자또는주식관련사채등의발행결과(자율공시)
유상증자또는주식관련사채등의발행결과(자율공시)
Large Shareholding Report (General)
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-21 | 유상증자또는주식관련사채등의발행결과(자율공시) |
| 2026-08-21 | 유상증자또는주식관련사채등의발행결과(자율공시) |
| 2026-08-21 | Large Shareholding Report (General) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-10 | Material Event Report (CB Issuance Decision) |